Drugs / HSP-CAR30
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04653649 | Sep 2020 → Dec 2023 | Hodgkins lymphoma, T-cell non-Hodgkin lymphoma | Sant Pau Research Institute | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HSP-CAR30 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04653649 ↗ |
| Modality | Cell therapy | “HSP-CAR30 is a cell suspension of genetically modified T-cells” NCT04653649 ↗ |